In this Science segment, we examine the European Medicines Agency’s recent decision to recommend granting marketing authorization for the anti-Alzheimer’s drug lecanemab. This follows an earlier rejection of its commercialization, citing concerns that the risks outweighed the benefits. So, what changed, and is this drug really the miracle treatment for Alzheimer’s that some claim it to be?
Trending
- Gavin Casalegno, Lana Condor Vs. Shark
- Syria slams new Israeli incursion in southern Daraa province
- Why Péter Magyar is reluctant to align with the EU on Ukraine
- Karlovy Vary Film Festival Sets Supersized Red Carpet for Everybody
- French hospitals 'better prepared': 'Important lessons learned from deadly 2003 heatwave'
- Get an Exclusive First Look at ‘Minions and Monsters’
- Iraq's push for bigger OPEC quota driven by revenue pressures, new oil investment
- Geothermal energy: Investment needed to develop new tech
